Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
CONCLUSION: Ropeginterferon alfa-2b, although at only half the number of injections, is as safe and effective as Peg-IFN-α2a for genotype 2 CHC. A phase 3 study to confirm safety and efficacy of Ropeginterferon alfa-2b in genotype 2 CHC is ongoing.
PMID: 33077341 [PubMed - as supplied by publisher]
Source: J Formos Med Assoc - Category: General Medicine Authors: Hsu SJ, Yu ML, Su CW, Peng CY, Chien RN, Lin HH, Lo GH, Su WW, Kuo HT, Hsu CW, Yang SS, Yang SS, Tseng KC, Qin A, Huang YW, Chuang WL Tags: J Formos Med Assoc Source Type: research
More News: European Medicines Agency (EMA) | General Medicine | Hepatitis | Hepatitis C | Pegasys | Study | Taiwan Health | Virology